Drugs / Dengue Tetravalent Vaccine (TDV)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04313244 | May 2021 → Feb 2022 | dengue disease | Takeda | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dengue Tetravalent Vaccine (TDV) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04313244 ↗ |
| Modality | Vaccine | “live-attenuated tetravalent dengue vaccine (TAK-003)” PMID 41058426 ↗ Oct 2025 |
| Route | Subcutaneous | “TDV subcutaneous injection” NCT04313244 ↗ |